Verlukast-D6, with the CAS number 153698-86-3, is a chemical compound that belongs to the class of leukotriene receptor antagonists. It is primarily utilized in the treatment of asthma and allergic rhinitis by inhibiting the action of leukotrienes, which are inflammatory mediators that contribute to bronchoconstriction and mucus production. The "D6" designation typically indicates that the compound is a deuterated form, meaning that certain hydrogen atoms in the molecule are replaced with deuterium, a heavier isotope of hydrogen. This modification can enhance the pharmacokinetic properties of the drug, potentially improving its efficacy and reducing side effects. Verlukast-D6 is characterized by its ability to selectively bind to the cysteinyl leukotriene receptor, thereby blocking the effects of leukotrienes on airway tissues. Its chemical structure includes specific functional groups that contribute to its biological activity and solubility. As with many pharmaceuticals, the safety and efficacy of Verlukast-D6 are evaluated through clinical trials before it is approved for therapeutic use.

Verlukast-D6

153698-86-3: Verlukast-D6, with the CAS number 153698-86-3, is a chemical compound that belongs to the class of leukotriene receptor antagonists. It is primarily utilized in the treatment of asthma and allergic rhinitis by inhibiting the action of leukotrienes, which are inflammatory mediators that contribute to bronchoconstriction and mucus production. The "D6" designation typically indicates that the compound is a deuterated form, meaning that certain hydrogen atoms in the molecule are replaced with deuterium, a heavier isotope of hydrogen. This modification can enhance the pharmacokinetic properties of the drug, potentially improving its efficacy and reducing side effects. Verlukast-D6 is characterized by its ability to selectively bind to the cysteinyl leukotriene receptor, thereby blocking the effects of leukotrienes on airway tissues. Its chemical structure includes specific functional groups that contribute to its biological activity and solubility. As with many pharmaceuticals, the safety and efficacy of Verlukast-D6 are evaluated through clinical trials before it is approved for therapeutic use.

<p>Applications A receptor antagonist for the treatment of respiratory diseases.<br>References Morgenstern, R., et al.: Biochem. J., 260, 577 (1989), Armstrong, R., et al.: Chem. Res. Toxicol., 10, 2 (1997), Larsen, J., et al.: Ann. Allergy, 71, 103 (1993),<br></p>

CAS 153698-86-3

Verlukast-D6

Verlukast-d6

Ref: TR-V128502